本文已被：浏览 2323次 下载 2194次
投稿时间：2023-04-16 网络发布日期：2023-06-20
投稿时间：2023-04-16 网络发布日期：2023-06-20
中文摘要: 随着免疫治疗的不断发展，晚期非小细胞肺癌患者的诊疗也逐渐精准和完善。免疫检查点抑制剂在程序性死亡配体1（PD-L1）高表达的非小细胞肺癌患者中的临床获益明显，但在低表达的患者中的效果仍不确切。本文针对PD-L1低表达的晚期非小细胞肺癌患者可选择的治疗方案进行综述，旨在为该人群的治疗提供参考和选择。
Abstract:With the continuous development of immunotherapy, the treatment of patients with advanced non-small cell lung cancer (NSCLC) is gradually becoming more and more precise. The clinical benefit of immune checkpoint inhibitors in patients with NSCLC with positive programmed cell death-ligand 1 (PD-L1) expression is obvious, but the effect in patients with negative expression remains inexact. This article reviews the treatment options available for advanced NSCLC patients with negative PD-L1 expression, aiming at providing references and options for their treatment.
keywords: Programmed death-ligand 1 Non-small cell lung cancer, advanced Immune checkpoint inhibitor Pabolizumab Atezolizumab Caerulizumab Nivolumab Ipilimumab Bevacizumab
文章编号： 中图分类号：R734.2 文献标志码：A
基金项目:国家自然科学基金面上项目 (82273162)
附件
| Author Name | Affiliation |
| LIU Ying, ZHOU Guoren | The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China |
引用文本：
刘颖, 周国仁.PD-L1低表达晚期非小细胞肺癌患者药物治疗进展[J].中国临床研究,2023,36(6):801-804.
刘颖, 周国仁.PD-L1低表达晚期非小细胞肺癌患者药物治疗进展[J].中国临床研究,2023,36(6):801-804.